| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.008 | 0.9 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.9 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.0074 | 0.9 |